Emerging pharma residue contaminants: Occurrence, monitoring, risk and fate assessment – A challenge to water resource management

Water is one of the important gifts to mankind. In recent days the accessibility of pharmaceuticals in the environment is progressively a worldwide concern. The significant wellspring of these contaminations in water assets is drugs for human use or veterinary medications. Intermediates, active metabolites and raw materials present in water from pharmaceutical industry waste because of incomplete sewage treatment systems. Various pharmaceutical components such as analgesic/antipyretics such as Ibuprofen (57.9–104 ng/L), Diclofenac (17–129 ng/L), antibiotics such as Sulfamethoxazole (28.7–124.5 ng/L), Sulfamethazine (29.2–83.9 ng/L), Azithromycin (10–68 ng/L), psychiatric drug such as Carbamazepine (9.3–92.4 ng/L), stimulants such as caffeine greater than 55 ng/L, antidepressants, antihypertensive, contraceptives etc., are present in water resources and have been detected in mg/L to μg/L range. The synergic effects and ecotoxicological hazard assessment must be developed. Studies demonstrate that these drugs might cause morphological, metabolic and sex alterations on sea-going species, and interruption of biodegradation activities. Hazard analysis and assessments are in progress. However, the conventional effluent treatment methods are not sufficient to remove API (active pharmaceutical ingredients) from this water effectively. There is necessitate for continuous monitoring of the pharmaceutical compounds in aquatic ecosystem to save the environment and living form of lives from health hazards. This work highlights the hazards, environmental assessment and the mitigation measures of pharmaceutical pollutants.